Trial Profile

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HM-97662 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Hanmi Pharmaceutical

Most Recent Events

30 Apr 2025 Planned number of patients changed from 140 to 170.
30 Apr 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Jan 2028.
17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com